GlobalData on MSN
FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
The decision is based on results from the Phase III MAJESTY study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results